Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-410-5 | CAS number: 2756-56-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Isobornyl propionate is not considered a skin sensitiser based on information of the analogue Isobornyl acetate. This substance is tested in an in vitro battery using DPRA, KeratinoSens and hClat (OECD TG 442 C/D and E), where it is negative in the first two assays and positive in the latter. An LLNA up to 25% was negative.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vitro
- Type of information:
- read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: read-across information from an analogue is used
- Justification for type of information:
- The skin sensitisation information is based on read across from Isobornyl acetate. The read across rationale is presented in the Skin sensitisation Endpoint summary. The read across rationale is also presented there.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- read-across source
- Key result
- Parameter:
- other: Mean Peptide depletion of Cysteine and Lysine (%)
- Value:
- 0.2
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- not applicable
- Remarks on result:
- other: Negative
- Remarks:
- Results obtained from DPRA
- Key result
- Run / experiment:
- other: Mean Percent Peptide Depletion (%)
- Parameter:
- other: Cysteine reactivity
- Value:
- 0.4
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from DPRA
- Key result
- Run / experiment:
- other: Mean Percent Peptide Depletion (%)
- Parameter:
- other: Lysine reactivity
- Value:
- 0
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from DPRA
- Key result
- Parameter:
- other: EC 1.5 (µM)
- Remarks:
- The concentration for gene induction above the threshold (1.5 fold) as compared to the DMSO solvent controls
- Value:
- 2 000
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from Keratinosens assay
- Key result
- Run / experiment:
- mean
- Parameter:
- other: IC50 (µM)
- Remarks:
- MTT
- Value:
- 170.14
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from Keratinosens assay
- Key result
- Parameter:
- other: Imax
- Remarks:
- Maximal Induction
- Value:
- 0.95
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from Keratinosens assay
- Parameter:
- other: CImax (µM)
- Remarks:
- Concentration for maximal gene induction
- Value:
- 3.91
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from Keratinosens assay
- Key result
- Run / experiment:
- other: Experiment 3 and 4 (average)
- Parameter:
- other: EC200% for CD54 (μg/mL)
- Value:
- 74.5
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Positive
- Remarks:
- Result obtained from h-CLAT with read-across substance Isobornyl acetate (CAS 125-12-2)
- Run / experiment:
- other: Experiment 2
- Parameter:
- other: EC150% for CD86 (μg/mL)
- Value:
- 80
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Remarks on result:
- other: Negative
- Remarks:
- Result obtained from h-CLAT
- Interpretation of results:
- other: Not a skin sensitiser
- Remarks:
- according to EU CLP (EC no. 1272/2008 and its amendments).
- Conclusions:
- Isobornyl propionate is not a skin sensitiser based on negative results of Isobornyl acetate in the DPRA and the KeratinoSens, despite positive results in the h-Clat.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
For Isobornyl propionate a human maximization test is available which was negative up to 10% but this information is insufficient for fullfilling the requirements. Therefore information from Isobornyl acetate is presented which can be used for read across. First the in vitro information data are presented, followed by the LLNA. The LLNA is considered supporting because the concentration used was up to 25%, without a clear indication for not using 100%, The read across rationale is presented thereafter.
In vitro test: DPRA assay (OECD422C) with Isobornyl acetate
The Direct Peptide Reactivity Assay (similar to OECD TG 442C) was used in a weight-of-evidence approach to assess the skin sensitizing potential of the test substance. Synthetic peptides containing cysteine or lysine were reacted with 100 mM test article for 24± 2 hours in a ratio of 1:10 (cysteine) or 1:50 (Lysine). Acetonitrile was used as vehicle and Cinnamic aldehyde was used as positive control. After the incubation period the extent of peptide depletion was analyzed using High Performance Liquid Chromatography (HPLC) coupled with ultra-violet (UV) spectrometric detection. The positive control resulted in 75.4 and 59.8% depletion of the respective peptides. The test substance gave a mean peptide depletion of 0.4% and 0.0% for Cysteine and Lysine, respectively. The mean peptide depletion of Cysteine and Lysine was 0.2%. Based on these results, the test is negative.
In vitro battery: Keratinosens assay (OECD422D) with Isobornyl acetate
A keratinosens assays was performed similar to OECD TG 442D. This assay was used in a weight-of-evidence approach to assess the skin sensitizing potential of the test substance. The test article, dissolved in DMSO, was tested in three definitive keratinosens assays. Each definitive assay included a set of 4 plates (3 for gene induction, 1 for cytotoxicity assessment). The test articles were tested at 12 concentrations ranging from 0.977 to 2000 µM. The positive control, Cinnamic Aldehyde, was tested at 5 concentrations ranging from 4 to 64 µM. The experimental design of this study consisted of three definitive assays to determine the maximal induction(Imax),the concentration for maximal gene induction (CImax), the EC1.5 value(concentration for a statistically significant induction of 50% above solvent controls), and a mean IC50 (concentration leading to 50% viability as compared to solvent controls) for the test articles. For each definitive assay, the KeratinoSens cells were cultured in quadruplicate plates for 24 hours, treated with the test articles for 48 hours, and assessed for luciferase induction (3plates) and cytotoxicity (1 plate). For the test item an EC 1.5 value > 2000 µM, a mean IC50 of 170.14 µM, a maximal induction of 0.95 and a Concentration for maximal induction of 3.91 µM was found. The positive control, Cinnamic aldehyde resulted in an EC 1.5 value of 14.55 µM and the mean IC50 was > 64 µM. Based on these results, the test is negative.
In vitro battery: h-CLAT assay (OECD422E) with Isobornyl acetate
The potential of test substance to induce the cell membrane markers CD86 and CD54 expression was evaluated in a GLP-compliant Human Cell Line Activation Test (h-CLAT) according to OECD TG 442E. The test substance was incubated with human monocytic leukemia cell line THP-1 for ca. 24 hours at 37°C and membrane marker expression (CD86 / CD54) was measured by flow cytometry. In order to determine the concentrations suitable for the main experiment two pre-tests (non-GLP) were performed. Cells were exposed to 9 concentrations of the test substance and cytotoxicity was determined thereafter by propidium iodide (PI) intercalation into the DNA. The CV75 value (= estimated concentration that affords 75% cell viability) was determined by linear regression from the concentration response curve to be 88 μg/mL (result of the 2nd pre-test). In the main test after 24 hour exposure THP-1 cells were stained with FITC labelled anti-human- CD86/ anti-human-CD54 antibody and propidium iodide and the fluorescence intensity was analysed using flow cytometry. A total of 3 valid experiments were performed (the first one was invalid). At concentrations used in the valid main experiments the test substance (500 x stock solutions) was soluble in DMSO and soluble in 0.2% DMSO (final concentrations). After 24 hours precipitates were not noticed in any concentration. In experiment 2 the cell viability was too low when the EC150% and EC200% were exceeded and is negative. In experiment 3 the EC150% was exceeded in CD86 and EC200% in CD54 both at >=88 ug/ml and thus considered positive. In experiment 4 the EC200% was exceeded in CD54 at >=88 ug/ml and therefore considered positive. In 2/3 tests a positive result was found and therefore the substance induces dendritic cell activation in the h-CLAT under the test conditions chosen.
Isobornyl propionate LLNA
The skin sensitisation potential of the test substance has been tested using the Local Lymph Node according to OECD TG 429 and GLP principles (Syngenta, 2007). Test concentrations were set by the sponsor based on acute oral toxicity data. Per dose group 4 female CBA/Ca mice were included. The application of the test substance at concentrations of 1, 2.5, 5, 10 and 25% (w/v) in a vehicle of 1:3 EtOH:DEP for 3 consecutive days did not result in an increase in the proliferation index of more than 3 fold (1.7 fold for the 25%) compared to the vehicle control. The positive control hexylcinnamaldehyde proved the validity of the protocol. No effects on body weight, skin irritation nor systemic toxicity (clinical signs) were reported. Based on the results, the substance was not considered to be a skin sensitizer.
Overall conclusion: The test substance does not have a skin sensitization potential based on the key information of three in vitro skin sensitization tests. The ITS proposed by Bauch et al. 2012, presents that when 2/3 in vitro results are negative the substance can be considered a non-skin sensitiser. In addition, the LLNA is negative up to 25%. Reference: Bauch, C., Kolle, S.N., Ramirez, T., Eltze, T., Fabian E., Mehling, A., Teubner, W., van Ravenzwaay, B., Landsiedel, R., 2012, Putting the parts together: Combining in vitro methods to test for skin sensitizing potentials, Regul. Toxicol. Pharmacol., 63, 489–504.
Skin sensitisation of Isobornyl propionate (Cas no. 2756-56-1) using read across from Isobornyl acetate (125-12-2).
Introduction and hypothesis for the analogue approach
Isobornyl propionate has an exo-1,7,7-Trimethylbicyclo[2.2.1]heptane-2-ol (Isobornyl alcohol) backbone to which a propionic ester group is attached. For this substance insufficient skin sensitisation information is not available. In accordance with Article 13 of REACH, lacking information can be generated by other means i.e. applying alternative methods such as QSARs, grouping and read-across. The analogue approach is selected since for the structurally related analogues Isobornyl acetate information is available which can be used for read across.
Hypothesis: The skin sensitisation of Isobornyl propionate is the same as for Isobornyl acetate
Available information: Isobornyl propionate was tested in a Human maximization test and no sensitisation was observed at a concentration of 10% (RIFM information). For Isobornyl acetate a battery of in vitro tests are available: DPRA, KeratinoSens and h-Clat (OECD TG 442C/D and E, respectively), which were negative, negative and positive, respectively. As two out of 3 in vitro tests are negative, it is not considered a skin sensitiser. Also for Isobornyl acetate a Local lymph node assay is available (according to OECD 429, Rel. 2) which is negative for concentrations up to 25%.
Target chemical and source chemical(s)
Chemical structures of the target chemical and the source chemical(s) are shown in the data matrix, including relevant physico-chemical properties.
Purity / Impurities
Isobornyl propionate is a mono-constituent >=88%, with impurities similar to the parent substance and < 10%.
Analogue approach justification
According to REACH Annex XI 1.5 read-across can be used to replace testing when the similarity can be based on a common backbone and a common functional group. When using read-across the result derived should be applicable for C&L and/or risk assessment and it should be presented with adequate and reliable documentation, which is presented below.
Analogue selection:For Isobornyl propionate the one methyl shorter Isobornyl acetate was selected as an analogue being the closest analogue for which skin sensitisation information is available. E.g. for Isobornyl butyrate no such information was found on the ECHA site or in the RIFM database.
Structural similarities and differences:Isobornyl propionate and Isobornyl acetate have the same backbone and functional ester group. The only difference between the two is the propionate and acetate group, respectively, which will result in a higher molecular weight of the first one.
Skin absorption:For Isobornyl –propionate and acetate the liquid appearance, molecular weight and other physico-chemical properties i.e. log Kow indicate that some skin absorption can occur and that there is only a minimal difference between the two.
Reactivity: Isobornyl-propionate and acetate are similarly reactive because these are almost the same substances with one methyl difference in the alkyl-ester chain, which has a slight impact on the log Kow but not on reactivity. The OECD Toolbox 2.2 shows a similar non-reactive profile (data not shown).
Uncertainty of the prediction: There are no uncertainties other than those already addressed above.
Data matrix
The relevant information on physico-chemical properties and toxicological characteristics are presented in the data matrix.
Conclusions for hazard and risk assessment
For Isobornyl propionate limited skin sensitisation information is available insufficient to fulfil the endpoint. Information from two analogues can be used for read across. When using read across the result should be applicable for classification and labelling and risk assessment as well as presented with reliable and adequate documentation. This documentation is presented in the current document. For Isobornyl acetate results of in vitro skin sensitisation is available (OECD TG 442 C/D and E) and an LLNA (OECD TG 429 up to 25%) which both present absence of skin sensitisation.
The ITS proposed by Bauch et al. 2012, presents that when 2/3 in vitro results are negative the substance can be considered a non-skin sensitiser. In addition, the LLNA is negative up to 25%.
Using this information for Isobornyl propionate this substance is not a sensitizer either.
Final conclusion on hazard and risk assessment: Isobornyl propionate is not a skin sensitizer.
Data matrix to support the read across to Isobornyl propionate from Isobornyl acetate
Common names
Isobornyl propionate
Isobornyl acetate
Target
Source
Chemical structures
CAS no.
2756-56-1
125-12-2
EINECS
220-410-5
204-727-6
REACH registration
2018
Registered
Empirical formula
C13H22O2
C12H20O2
Molecular weight
210.32
196.29
Phys-chem properties
Physical state
Liquid
Liquid
Log Kow (measured)
5.0 (IFF measured)
4.3 (Simonich, EpiSuite)
Human health
Skin sensitisation
Not sensitising
(Read across)
Not sensitising based on Negative results in DPRA an KeratinoSens
(OECD TG 442C and D), despite positive in h-CLAT (OECD TG 442E)
Not sensitising
(Read across)
Not sensitising
(OECD TG 429 up to 25%)
Reference
Bauch, C., Kolle, S.N., Ramirez, T., Eltze, T., Fabian E., Mehling, A., Teubner, W., van Ravenzwaay, B., Landsiedel, R., 2012, Putting the parts together: Combining in vitro methods to test for skin sensitizing potentials, Regul. Toxicol. Pharmacol., 63, 489–504.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Respiratory sensitisation can be assessed using human data such as indicated in R7.3.5.2 of the ECHA guidance (2017) that indicate respiratory reactions e. g. from consumer experience or occupational exposure. In case no such data are available the respiratory sensitisation can be assessed using the integrated evaluation strategy for respiratory sensitisation data in the ECHA guidance (R7A, Fig. 7.3-2, 2017), which says that if the substance is not a skin sensitiser, it is unlikely to be a respiratory sensitiser.
Justification for classification or non-classification
The substance dose not need to be classified for skin or respiratory sensitisation according to EU CLP (EC No.1272/2008 and its amendments).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.